A pivotal trial of GLPG1690 in Idiopathic Pulmonary Fibrosis (IPF) : ISABELA 2

Trial Profile

A pivotal trial of GLPG1690 in Idiopathic Pulmonary Fibrosis (IPF) : ISABELA 2

Planning
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs GLPG 1690 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ISABELA 2
  • Sponsors Galapagos NV
  • Most Recent Events

    • 16 Apr 2018 New trial record
    • 12 Apr 2018 According to a Galapagos NV media release, this ISABELA program is expected to start dosing in the second half of 2018. A total of 1500 patients are planned to enrol in this program.
    • 12 Apr 2018 According to a Galapagos NV media release, based on feedback from the FDA and EMA, company announces the design of this study. The ISABELA Phase 3 program is intended to support the New Drug Application (NDA) and the Market Authorization Application (MAA) submissions in respectively the USA and EU for GLPG1690 in Idiopathic Pulmonary Fibrosis (IPF).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top